Clinical Trial Detail

NCT ID NCT02381080
Title Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

mantle cell lymphoma

marginal zone B-cell lymphoma

follicular lymphoma

CLL/SLL

Therapies

Erythromycin + Ibrutinib + Voriconazole

Age Groups: adult

No variant requirements are available.